Aurora Sees Lower Losses in Q1 2027 as International Growth Offsets Domestic Decline
Aurora Cannabis Inc. reported Q1 FY2027 (three months ended June 30, 2026) net revenue of $67.6M, down 9% year over year, with net loss of $4M, down 80%. Gross profit rose 6% to $35.6M. International medical cannabis revenue rose 17% to $43.3M, while Canadian medical revenue fell 25% to $20.7M. Safari Flower renewed EU-GMP certification.
How this was made
The 30-second read
Why it matters
Q1 FY2027 shows improving losses and higher gross profit, but Canadian medical revenue declined 25% YOY, attributed to VAC reimbursement rate reductions effective April 1, 2026. International medical revenue rose 17% YOY, mainly from Germany, and a wholly owned subsidiary renewed EU-GMP certification for its Ontario facility, supporting the company’s EU manufacturing capacity strategy.
Market read
Traders can update models for ACB’s revenue mix and margin drivers based on the reported quarter and the explicit reimbursement-rate headwind versus international offset.
What to watch
Excise taxes fell to a 14% rate, but sales and marketing rose due to shipping and freight, which could pressure margins if logistics costs persist.
Background
Aurora Cannabis (ACB) is transitioning from Canadian medical and consumer cannabis toward international medical cannabis, while navigating reimbursement and regulatory changes.
Ticker impact
Aurora Cannabis reported Q1 FY2027 net revenue of $67.6M, net loss of $4M, and an 80% decline in net losses, citing VAC reimbursement changes and international growth.
Near-term volatility likely, with traders weighing loss improvement versus the Canadian reimbursement headwind and consumer cannabis wind-down.
The article provides concrete quarterly financials and a specific policy driver (VAC reimbursement rate cut effective April 1, 2026) plus a countervailing international Germany growth offset.
Market effects
Highlights how reimbursement-rate cuts can pressure Canadian medical cannabis revenue while EU-GMP capacity and international sales can partially offset.
Emphasizes Germany as a key growth driver for international medical cannabis revenue.
Reinforces that export-market regulatory tightening and GMP standards are central to scaling medical cannabis outside the US.
Counterpoint
The gross profit increase is partly driven by a $12.6M fair-value biological asset gain, which may not reflect sustainable operating cash generation.
Key entities
- public_companyAurora Cannabis Inc.
Reported Q1 FY2027 net revenue, gross profit, and net loss, and discussed drivers including VAC reimbursement changes and international growth.
- subsidiarySafari Flower Company
Wholly owned subsidiary that renewed EU-GMP certification for its Ontario facility.
- regulatory_programVAC reimbursement program
Reimbursement program change that lowered compensation rates to cannabis producers from $8.50/g to $6/g effective April 1, 2026.
- executiveMiguel Martin
Executive Chairman and CEO who commented on international market difficulty and potential partnership opportunities tied to US rescheduling.
